Sanofi-aventis enters definitive agreement to acquire Genzyme
Sanofi-aventis and Genzyme Corporation announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion.
Sanofi-Aventis , the largest French pharmaceutical producer, said on Monday that it extended its offer to buy US biotechnology group Genzyme shares to April.